[HTML][HTML] Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

M Omata, AL Cheng, N Kokudo, M Kudo, JM Lee… - Hepatology …, 2017 - Springer
There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Clinical studies with curcumin

CH Hsu, AL Cheng - The molecular targets and therapeutic uses of …, 2007 - Springer
Curcumin has long been expected to be a therapeutic or preventive agent for several major
human diseases because of its antioxidative, anti-inflammatory, and anticancerous effects …

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

AL Cheng, C Hsu, SL Chan, SP Choo, M Kudo - Journal of hepatology, 2020 - Elsevier
Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo …

AL Cheng, YK Kang, Z Chen, CJ Tsao, S Qin… - The lancet …, 2009 - thelancet.com
Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where
chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and …

[HTML][HTML] Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

RS Finn, S Qin, M Ikeda, PR Galle… - … England Journal of …, 2020 - Mass Medical Soc
Background The combination of atezolizumab and bevacizumab showed encouraging
antitumor activity and safety in a phase 1b trial involving patients with unresectable …

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

M Kudo, RS Finn, S Qin, KH Han, K Ikeda, F Piscaglia… - The Lancet, 2018 - thelancet.com
Background In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors
1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed …

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 …

J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky… - The Lancet, 2017 - thelancet.com
Background There are no systemic treatments for patients with hepatocellular carcinoma
(HCC) whose disease progresses during sorafenib treatment. We aimed to assess the …

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

T Yau, JW Park, RS Finn, AL Cheng, P Mathurin… - The Lancet …, 2022 - thelancet.com
Background Single-agent nivolumab showed durable responses, manageable safety, and
promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 …

[HTML][HTML] Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

AL Cheng, S Qin, M Ikeda, PR Galle, M Ducreux… - Journal of …, 2022 - Elsevier
Background & Aims IMbrave150 demonstrated that atezolizumab plus bevacizumab led to
significantly improved overall survival (OS) and progression-free survival (PFS) compared …

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

AX Zhu, RS Finn, J Edeline, S Cattan… - The Lancet …, 2018 - thelancet.com
Background Immune checkpoint blockade therapy has shown promising results in patients
with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of …